00:41 , Apr 6, 2019 |  BC Extra  |  Politics & Policy

CFIUS drawing line in sand on personal data

The Trump administration has further reinforced which kinds of life science investments will be off limits for foreign investors, as reports emerge that CFIUS is compelling two more Chinese firms to relinquish control over companies...
22:14 , Oct 11, 2018 |  BC Innovations  |  Strategy

Border security for China’s genomes

China’s policies on sharing genomic data have so far produced cumbersome but manageable hurdles for cross-border clinical trials and translational research. But the explosive growth of its genomics industry, and the backdrop of rising political...
00:07 , Sep 5, 2018 |  BC Extra  |  Company News

Management tracks: Agios, Radius

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said David Schenkein will step down as CEO and become executive chairman, effective Feb. 1, 2019. He will succeed Chairman John Maraganore, who is also CEO at Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)....
00:07 , Jun 28, 2018 |  BC Extra  |  Politics & Policy

Broader CFIUS jurisdiction may have implications for biotech

President Donald Trump said Wednesday he plans to use the Committee on Foreign Investment in the United States (CFIUS) to protect U.S. innovation, citing a House of Representatives bill that seeks to expand the agency's...
00:08 , Jun 26, 2018 |  BC Extra  |  Politics & Policy

Fresh challenge for Chinese investment in U.S. biopharma

The momentum of Chinese investment in the U.S. biopharma industry could be at risk as Trump administration officials made conflicting statements Monday as to whether the administration is considering restrictions on foreign investments in U.S....
21:02 , Apr 6, 2018 |  BioCentury  |  Emerging Company Profile

Tiny taxanes

NanOlogy LLC is using submicron particle production technology to rework chemotherapeutics into stable nano-sized particles and deliver them directly to disease sites. The technology could increase the efficacy and reduce the side effects associated with...
21:39 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

NanOlogy starts Phase IIa for NanoPac in prostate cancer

NanOlogy LLC (Fort Worth, Texas) began a Phase IIa trial to test NanoPac in prostate cancer patients scheduled for prostatectomy. The open-label, dose-escalation study will evaluate safety as its primary endpoint in up to 30...
20:45 , Nov 10, 2017 |  BC Week In Review  |  Company News

Biotest's Chinese takeover tripped up by U.S. security concerns

Biotest AG (Xetra:BIO) said on Nov. 7 that it withdrew its application for U.S. approval of a takeover bid by Tiancheng Pharmaceutical Holdings AG (Munich, Germany) after the Committee on Foreign Investment in the United...
23:45 , Nov 8, 2017 |  BC Extra  |  Company News

Biotest's Chinese takeover tripped up by U.S. security concerns

Biotest AG (Xetra:BIO) said on Tuesday it withdrew its application for U.S. approval of a takeover bid by Tiancheng Pharmaceutical Holdings AG (Munich, Germany) after the Committee on Foreign Investment in the United States (CFIUS)...
20:20 , Sep 22, 2017 |  BC Week In Review  |  Company News

DFB, CritiTech, U.S. Biotest form NanOlogy

DFB Pharmaceuticals LLC (Fort Worth, Texas), CritiTech Inc. (Lawrence, Kan.) and U.S. Biotest Inc. (San Luis Obispo, Calif.) formed NanOlogy LLC (Fort Worth, Texas) to develop nanoparticle drug-delivery technology to treat cancer. The newco's pipeline...